<DOC>
	<DOC>NCT02927925</DOC>
	<brief_summary>The purpose of this study is to assess the clinical efficacy and safety of daratumumab in relapsed or refractory natural killer/T-cell lymphomas (NKTCL).</brief_summary>
	<brief_title>A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Documented as histologically confirmed extranodal natural killer/Tcell lymphomas (NK/T)cell lymphoma, nasal type according to the World Health Organization (WHO) classification and the pathology report will be verified by the Sponsor Failed at least 1 line of chemotherapy and who, according to treating physician or investigator, is not candidate to receive other treatment modalities At least 1 measurable site of disease Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2 Received daratumumab or other antiCD38 therapies previously Previous allogenic stem cell transplant or autologous stem cell transplantation within 12 weeks before the first administration of the study drug Clinical symptoms of central nervous system involvement Known chronic obstructive pulmonary disease, known moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification Clinically significant cardiac disease, including:Myocardial infarction within 6 months before the first study agent administration, or unstable or uncontrolled disease/condition related to or affecting cardiac function (eg, unstable angina, congestive heart failure, New York Heart Association Class IIIIV); Uncontrolled cardiac arrhythmia (Common Terminology Criteria for Adverse Events [CTCAE] [most recent version] Grade 3 or higher) or clinically significant ECG abnormalities; Screening 12lead ECG showing a baseline QT interval as corrected QTc &gt;470 msec Seropositive for human immunodeficiency virus Active infection with hepatitis B or hepatitis C Abnormal laboratory values according to protocol defined parameters at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>